Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Rule 5635(C)(4)
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on innovative treatments for neurological diseases, announced the granting of inducement awards to three new employees. The Board’s Compensation Committee approved the issuance of non-qualified stock options to purchase a…
Kezar Life Sciences Puts Zetomipzomib IND for Lupus Nephritis on Clinical Hold
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology firm focused on developing innovative small molecules for immune-mediated diseases, has announced that its Investigational New Drug (IND) application for zetomipzomib, aimed at treating lupus nephritis (LN), has been placed on…
First Patient Enrolled in Phase I/IIa Trial for Lenti-HPV-07 Vaccine Against HPV-Induced Cancers
TheraVectys, a biotechnology firm focused on creating lentiviral vector-based vaccines and immunotherapies for infectious diseases and cancers, has announced the enrollment of the first patient in a Phase I/IIa clinical trial for its onco-therapeutic vaccine, Lenti-HPV-07. This trial aims to…
Medical Alert Monitoring Association Conference Highlights Innovations in Remote Care for Seniors
The Medical Alert Monitoring Association (MAMA) recently wrapped up its annual conference in Washington D.C. on September 24 and 25. The event gathered industry leaders, healthcare professionals, and advocates dedicated to supporting aging adults. Over two days, discussions centered on…
A2 Bio to Present EVEREST-1 Trial Data at SITC 2024
A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company focused on developing first-in-class logic-gated cell therapies to selectively target tumor cells while protecting healthy cells, has announced that six of its abstracts have been accepted for presentation at the…
Study Shows Kerecis Fish-Skin Outperforms in Diabetic Foot Ulcer Treatment
Kerecis, a leader in the use of fish skin and fatty acids for tissue regeneration, has announced the publication of significant study results in the New England Journal of Medicine Evidence. This research, involving 255 patients across 15 care centers…
Aulos Bioscience to Present Phase 2 Data for AU-007 at SITC Annual Meeting
Aulos Bioscience, an immuno-oncology company focused on advancing cancer care through innovative IL-2 therapeutics, has announced the presentation of encouraging safety and efficacy data from the Phase 2 dose expansion cohorts of its Phase 1/2 clinical trial for AU-007. This…
Peak Mobile Vascular Expands to the Midwest
Peak Mobile Vascular Access is expanding its services to the Midwest, aiming to offer its exceptional vascular access solutions—such as PICC lines, Midlines, and Peripheral IVs—to a wider audience. This strategic move ensures high-quality care and enhanced convenience for both…
FDA Approves Exact Sciences’ Cologuard Plus for Colorectal Cancer Screening
Exact Sciences Corp. (NASDAQ: EXAS), a prominent provider of cancer screening and diagnostic solutions, has announced that the U.S. Food and Drug Administration (FDA) has approved its next-generation multitarget stool DNA test, Cologuard Plus™. This test is now authorized for…
Summit Therapeutics Completes Enrollment in Phase III HARMONi Trial for 2L+ EGFRm NSCLC
Summit Therapeutics Inc. (NASDAQ: SMMT) has announced the completion of patient enrollment in its HARMONi clinical trial. This multi-regional Phase III study evaluates ivonescimab combined with platinum-doublet chemotherapy versus placebo with platinum-doublet chemotherapy for patients with epidermal growth factor receptor…
FDA Approves Neoadjuvant Opdivo® and Chemotherapy for Resectable Non-Small Cell Lung Cancer
Bristol Myers Squibb (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab) for adult patients with resectable non-small cell lung cancer (NSCLC) with tumors ≥4 cm or node-positive, and no known EGFR mutations…
HealthAxis and COPE Health Solutions Form Strategic Partnership to Enhance Value-Based Care
HealthAxis, a leader in healthcare administration technology, has partnered with COPE Health Solutions (CHS), a specialist in value-based care and population health management. This strategic collaboration aims to provide comprehensive, end-to-end solutions for health plans and providers engaged in value-based…